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Previous data have implicated both neuronal activity and dopamine (DA)
autoreceptor activation in the modulation of Nur receptor expression in dopamine
neurons. Since dopamine receptor antagonists block the autoreceptors but also alter
dopamine release and dopamine neuron activity, the mechanism responsible for gene
expression is unclear. We hypothesized that blocking the stimulation of dopamine
autoreceptors will be the mechanism that causes the induction of the nuclear receptor
genes. To test this hypothesis, we treated 78 mice (1hr or 4hr incubation periods) with
either a dopamine D2 receptor agonist (quinpirole), a D2 receptor antagonist (sulpiride or
haloperidol) or J-butyrolactone (GBL), a drug that inhibits dopamine neuron activity.
HPLC and real time pCR was performed on each mouse to measure gene expression and
neurochemical levels. We found that D2 receptor treatments induced Nur receptor
expression levels and caused significant differences among neurochemical levels in the
striatum and nucleus accumbens.
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CHAPTER I
INTRODUCTION

1.1

Dopamine Function and Importance
Dopamine is an essential neurotransmitter found throughout the brain and

concentrated within the basal ganglia (Cooper et al. 2003). Dopamine is the most recent
catecholamine neurotransmitter to be discovered and probably one of the most important
transmitters to be found due to its relevance in disease states of certain CNS disorders
such as Parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder
(ADHD), which has annually costs of billions of dollars each year for therapeutic
treatments. The majority of dopamine in the brain originates from neurons located in
substantia nigra pars compacta and ventral tegmental area. The dopamine neurons in the
substantia nigra pars compacta innervate the striatum (nigrostriatal dopamine system)
while those in the ventral tegmental area innervate the prefrontal cortex (mesocortical
dopamine system) and the nucleus accumbens, amygdala and hippocampus (mesolimbic
dopamine system).
The nigrostriatal dopamine system is an important component of the basal
ganglia, a structure found to be directly involved in motor control, which has been found
to be dysfunctional in Parkinson’s disease. Parkinson’s disease results from 80-90% loss
of dopaminergic neurons in the nigrostriatal pathway and results in impaired motor
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movements and speech disorders (Lang et al 1998a, and 1998b; Steece-Collier et al.
2002). Dopamine neurotransmission from the neurons in the ventral tegmental area are
involved in the regulation of reward and motivation as well as cognitive function.
Abnormalities in dopamine neurotransmission have been demonstrated in schizophrenia,
specifically elevated subcortical dopamine neurotransmission and impaired mesocortical
dopamine neurotransmission (Seeman, P. Synapse, 1987 and Carlson et al. 2001).
Dysfunction of mesolimbic dopamine neurons have also been implicated in disorders
such as ADHD and addiction (Solanto, M.V. 2002).
Dopamine is produced via a cascade of enzymes working together to create the
final product. The basic amino acid tyrosine serves as the precursor to dopamine, which
is converted to L-DOPA via tyrosine hydroxylase (TH) the rate limiting enzyme during
dopamine production. L-DOPA is then converted to dopamine by DOPA decarboxylase
(DDC), the final enzyme necessary for the conversion of tyrosine into dopamine.
Additionally, tetrahydrobiopterin (BH4) is an essential cofactor for TH. BH4 is
synthesized from GTP via three enzymes; the final and rate-limiting enzyme is GTP
cyclohydrolase (GTPCH). Once synthesized, dopamine is concentrated into synaptic
vesicles via the vesicular monoamine transporter (VMAT2) for release into the synapse.
Following synaptic release, dopamine can be actively taken back up into the synaptic
terminal by the dopamine transporter (DAT) or metabolized by the enzymes monoamine
oxidase and/or catechol-o-methyltransferase to the metabolites 3,4 dihydroxyphenylacetic
acid (DOPAC) and homovanillic acid (HVA). Dopamine carries out its function via
binding to receptors both postsynaptic and presynaptic. There are two categories of
dopamine receptors known as D1 like (D1 and D5) and D2 (D2, D3 and D4) like. A
2

receptor of major importance is the D2 receptor which is known two have two isoforms,
D2S, the presynaptic autoreceptor, and D2L, the postsynaptic receptor (Usiello et al.
2000). These receptors are major targets of many antipsychotic medications such as
haloperidol used to treat schizophrenic patients and recent research has shown that these
receptors could serve as essential targets for future drug development which can be used
to target specific isoforms of a particular receptor ablating non specific binding and the
side effects that result.

1.2

Nur Receptor Subfamily Expression
Nurr1 is an immediate early gene that is expressed in dopamine neurons in the

substantia nigra and the ventral tegmental area (Zetterstrom et al. 1997; Castillo et al.
1998; Saucedo-Cardenas et al. 1998). Previous research has shown that Nurr1 is
essential for the proper differentiation of these dopamine neurons as shown in Nurr1
knockout (-/-) mice. These mice do not survive after birth due to inability to feed and
problems congenital hypoventilation (Zetterstrom et al. 1996a, Saucedo-Cardenas et al.
19998, Castillo et al. 1998, Nsegbe et al. 2004). Additionally, the Nurr1 -/- newborn pups
have profound deficits of dopamine in the midbrain and striatum along with the absence
of most midbrain dopaminergic neuron markers including TH, GTPCH, DAT, VMAT2,
and DDC (Zetterstrom et al. 1996a, Saucedo-Cardenas et al. 19998, Castillo et al. 1998).
Additional experiments have implicated Nurr1 directly in controlling the expression of
these genes necessary for dopamine synthesis and regulation (Zetterstrom et al. 1996a,
Saucedo-Cardenas et al. 1998, Castillo et al. 1998). In vitro studies have shown that
Nurr1 can bind to the promoters of TH to induce reporter gene expression (Sakurada et
al. 1999; Maira et al. 1999). Additionally, Nurr1, when expressed in vitro, can increase
3

the expression of a reporter gene via the DAT and GTPCH promoters (Bannon et al.
2001; Gil et al. 2007). Previous studies with Nurr1 null heterozygous (+/-) mice have
shown that a reduction in Nurr1 causes decreased dopamine levels in the midbrain,
nucleus accumbens and prefrontal cortex, along with decreased TH activity in the nucleus
accumbens and striatum, however striatal dopamine levels remain normal (SaucedoCardenas et al. 1998; Zetterstrom et al. 1997). Additionally, reduced TH and GTPCH
mRNA levels have been reported in the Nurr1 +/- mice (Eells et al. 2006). Dopaminergic
neurons in Nurr1+/- mice also show greater vulnerability to neurotoxicants and impaired
survival in vitro as compared dopamine neurons in wild type mice, indicating that Nurr1
possesses a neuroprotective role in mature dopamine neurons (Le et al. 1999; Eells et al.
2002). This genotype allows for a possible application to study dopamine production and
neurotransmission during periods of altered Nurr1 expression.
Nurr1 along with two very closely related genes Nur77 and Nor1 are all orphan
nuclear receptors of the steroid/thyroid hormone receptor subfamily, categorized as part
of the Nur receptor subfamily. Each receptor in this family possesses distinct
characteristics of function, structure, and location of expression; however all share very
similar DNA binding properties. All are expressed in the CNS. Nur77 expression is
concentrated in dopaminoceptive areas such as the striatum and nucleus accumbens
(Zetterstrom et al. 1996b; Beaudry et al. 2000). At basal levels, Nur77 mRNA is barely
detectable in the dopamine neurons (Maheux et al. 2004). Data from Nur77 -/- mice
demonstrates that Nur77 has a role in regulating dopamine neurotransmission. Nur77 -/mice showed higher locomotor activity when placed in a novel environment as compared
to +/+ mice after quinpirole administration (Gilbert et al. 2006). Also, Nurr1 and TH
4

mRNA expression was altered in the Nur77 -/- mice. Specifically, TH mRNA expression
was elevated in dopamine neurons in the substantia nigra pars compacta and Nurr1
mRNA expression was increased in dopamine neurons in the substantia nigra pars
compacta and ventral tegmental area. (Gilbert et al. 2006). Gilbert et al. also reports that
haloperidol has an effect on DA turnover in the striatum of Nur77 +/+ mice, although
there is a greater effect on striatal DOPAC levels in Nur77 -/- mice. Additionally, D2R
antagonists have been shown to significantly increase Nur77 mRNA expression in
dopamine neurons (Maheux et al 2004). Collectively, these data demonstrate an
important involvement of Nur77 in dopamine neuron function and a close relationship
with Nurr1 such that these transcription factors may be able to compensate for the downregulation or improper function of the other.
Nor1 is also found in the dopaminoceptive areas of the striatum and nucleus
accumbens along with Nur77, with a wide distribution in the hippocampus, amygdala,
and cerebellum, but with no expression in dopamine neurons (Zetterstrom et al. 1996b).
Disruption of the Nor1 gene has demonstrated that it is involved in proper neuron
development, survival and axon guidance of neurons in the hippocampus (Ponnio and
Conneely et al. 2004). Nor1 function and regulation within dopaminergic neurons has
yet to be extensively studied in detail, however similar to Nur77, this gene can be
induced by antagonism of the D2 receptor (Maheux et al 2004). As Nur77, Nor1 and
Nurr1 all share similar DNA binding properties, expression of Nur77 and Nor1 could
produce similar effects on expression of dopamine neuron targets genes as Nurr1.
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1.3

Nur Receptor Subfamily Homology
The Nur receptors exemplify the same protein structural moiety of all

steroid/thyroid hormone nuclear receptors, which consists of an amino terminal domain,
DNA binding domain, and a carboxyl-terminal domain (Freedman and Luisi 1993).
Additionally Nurr1, Nur77, and Nor1 also share deeper homology when individually
compared to each other (Eells et al. 2000). The greatest structural homology found
between the three is among the DNA binding domain, in which there is greater than 90%
homology among all three (Milbrandt et al. 1988; Law et al. 1992; Ohkura et al. 1994).
As a result of previous research it is known that Nurr1 and Nor1 both show the greatest
homology as compared to Nur77 and Nurr1 or Nur77 and Nor1. This could be important
in transactivation properties of response elements due to lack of function of another
receptor. The three receptors also show similar homology to gene structure, as all of
them contain six translated exons with common exon/intron splice sites (Milbrandt et al.
1988; Hazel et al. 1988; Castillo et al. 1997; Ohkura et al. 1996). Nurr1 and Nor1 again
show greater similarity among each other by both possessing two 5’ untranslated exons
as compared to Nur77 which only contains one 5’ untranslated exon. There also exists an
exon/intron junction between the two zinc finger motif’s which is different from the other
nuclear receptor superfamily genes, which possess a conserved splice site different from
that of Nurr1, Nur77, and Nor1 (Eells et. al 2000).
In contrast to their strong homology, however there exist differences among
promoter elements among Nurr1, Nur77, and Nor1. They contain various combinations
of GC-rich, AP-1, Sp-1, CRE, CArG, and ETs like sequences (Ryseck et al. 1989;
Woronicz et al. 1995; Williams et al. 1993; Yoon and Lau 1993). The promoter regions
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contained within these genes have various response elements that can regulate Nurr1,
Nur77, and Nor1 by immediate early response pathways or delayed early response
pathways (Eells et al. 2000).
Nurr1, Nur77, and Nor1 must be able to bind to DNA to exert their function of
regulating mRNA expression so proteins can be produced which will carry out a specific
function. These genes bind DNA as monomers to an octomer sequence known as Nur77
binding response element (NBRE: AAAGGTCA) to which Nur77 has the highest affinity
followed by Nurr1 then Nor1 ( Wilson et al. 1991; Paulsen et al. 1995; Zetterstrom et al.
1996a). Receptor binding to NBRE is a result of the T-box and A-box located at the CTerminal end of the DNA binding domain. All three Nur receptors have been shown to
be able to bind as a homodimer to the Nur77 response element (NurRE), which is an
inverted repeat sequence of NBRE (Phillips et al. 1997 35). As a homodimer Nur77 has
a higher affinity for NuRE as compared to its monomeric state for NBRE and is able to
upregulate in vitro gene expression through this sequence (Phillips et al. 1997). Also,
Nurr1 and Nor1 have been shown to bind as homodimers on NurRE and cause
transactivation of gene expression though Nur77 homodimers have a greater probability
for dimerization than either of the other two homodimers formed (Maira et al. 1999).
Nur77 also possesses the ability to form heterodimers with Nurr1 and Nor-1, which has a
synergistic effect on reporter gene expression (Maira et al. 1999). Nur77 and Nurr1 are
also able to form heterodimers with retinoid X receptor (RXR) (Perlman et al. 1995).
Heterodimerization between RXR-Nur77/Nurr1 allows binding to hormonal response
elements in close proximity to genes that they regulate (Zetterstrom et al. 1996a). This
binding adds yet another complexity to the response elements that nuclear receptors are
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responsible for activating, which will in turn control specific genes regulated by these
response elements. Nurr1 has the highest affinity to RXR compared to RAR and Nur77
(Perlman et al. 1995). Heterodimerization between RXR and RAR will inhibit any
dimerization between Nurr1 or Nur77 and RXR (Perlman et al. 1995). Nor1 is unable to
form heterodimers with RXR (Perlman et al. 1995), and has been shown to be able to
interfere with Nurr1 and Nur77-RXR heterodimer signaling (Zetterstrom et al. 1996a).

1.4

Rationale
Currently the exact mechanism by which dopamine neurons are lost in

Parkinson’s disease is unknown, though it is known that individuals with this disorder
produce less dopamine in the nigrostriatal pathway. This results in the symptoms of
Parkinson’s disease such as the inability to carry out movement and inhibiting
uncontrolled movement (tremors). Also, schizophrenia is believed to be caused by an
over production of dopamine in the mesolimbic pathway and a lack of dopamine in the
mesocortical pathway. Nurr1 is known to be a direct contributor to the development of
dopaminergic neurons in the midbrain, therefore presenting a possible avenue for the
development of therapeutic treatments that directly stimulate dopamine neuron
production. Since Nur77 and Nor1 both share similar DNA binding domains to Nurr1,
they may present possible targets for future drug development. Dopamine agonist and
antagonist both affect dopamine production whether it is directly or indirectly. These
drugs offer the ability to study gene regulation as it relates to dopamine neuron function
and dopamine production.
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1.5

Objectives
The goal of the current study was to 1) determine the effect of antipsychotic

treatment on Nurr1, Nor1 and Nur77 expression concurrent with dopamine
neurochemistry, dopamine neuron gene expression, 2) determine the mechanism of
Nurr1, Nor1 and Nur77 expression in dopamine neurons, and 3) determine effect of
reduced Nurr1 expression on Nur77 and Nor1 expression in dopamine neurons.

1.6

Hypothesis
We hypothesize that haloperidol should stimulate dopamine release and decrease

intracellular dopamine. Dopamine agonist treatment should block dopamine release
therefore increasing intracellular dopamine. Due to the blockage of dopamine there
should be a downregulation of all genes necessary for dopamine production and
metabolism. Since these nuclear receptors are induced by haloperidol and implicated in
regulating expression of genes involved in dopamine production, we expect that
haloperidol will induce nuclear receptor expression in the substantia nigra and ventral
tegmental area and that this will result in elevation of dopamine neurotranmssion gene
expression. Since Nur77 and Nor1 share DNA binding properties with Nurr1, induction
of these genes is expected to influence expression of dopamine neurotransmission genes
regulated by Nurr1. To investigate this we measured expression of Nur77, Nor1 and
Nurr1 1 hour after haloperidol treatment and dopamine neuron gene expression 4 hours
after haloperidol treatment. Expression of TH, GTPCH, DAT, VMAT2, and DDC were
measured along with the major dopamine metabolite of levels (DOPAC and HVA) and
the essential cofactor for dopamine synthesis BH4.
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Previous data has implicated both neuronal activity and dopamine autoreceptor
activation in the modulation of Nur receptor expression in dopamine neurons. Since
dopamine receptor antagonists block the autoreceptors but also alter dopamine release
and dopamine neuron activity, the mechanism responsible for gene expression is unclear.
We expect that blocking the stimulation of dopamine autoreceptors will be the
mechanism that causes the induction of the nuclear receptor genes. To conduct this
experiment we treated mice with either a dopamine D2 receptor agonist, a D2 receptor
antagonist or J-butyrolactone, a drug that inhibits dopamine neuron activity and
subsequent dopamine release and autoreceptor activation and measured Nurr1, Nur77 and
Nor1 expression in the ventral tegmental area and substantia nigra pars compacta.
Additionally, dopamine and metabolite levels and BH4 levels were measured.
Due to the similarities in the regulation of expression between these nuclear
receptors, we propose that altered expression of Nurr1 will influence the expression of
Nur77 and Nor1 in dopamine neurons. To investigate this we measured Nur77 and Nor1
in Nurr1 +/- and +/+ mice. This allowed us to determine the effects Nurr1 downregulation has on the other members of the Nur77 receptor subfamily. This data should
provided information important to determining the exact roles that Nur77 and Nor-1 are
responsible for carrying out during periods of Nurr1 arrest in midbrain dopaminergic
neurons along with neurotransmitter production.
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CHAPTER II
MATERIALS AND METHODS

2.1

Animals
Ninety day old male HSD: ICR Outbred Male Mice purchased from Harlan

Bioproducts for Science for the purpose of this study. Animals were housed at
Mississippi State University in an AAALAC accredited facility on 12 hour light/dark
cycle with food and water available at liberty. A total of 79 animals were used in this
study as shown in Table 2.1. Thirty two of the 79 animals were used for systemic
haloperidol and saline injections at two different time intervals of 1-hour and 4-hours.
Thirty two other animals were subjected to systemic injections of quinpirole, sulpiride,
GBL, or saline solution. The final 14 animals were Nurr1 +/+ or +/- mice that were used
to perform experiments to determine the differences expressed in the Nur77 receptor
subfamily due to genetic differences.

Table 2.1 Number of animals sacrificed in each experiment.

1-Hr Treatment
4-Hr Treatment

Saline
16
8

Haldol
8
8

GBL
9

Sulpiride
8

Quinpirole
8

Nurr1 +/+ or +/Total

23

16

9

8

11

8

Non treated

14
14

2.2

Dosage Regimen
Haloperidol was dissolved in acetic acid and was administered intraperitoneal (IP)

at a dose of 1mg/kg. Saline acetic acid solution served as our control treatment. Mice
were sacrificed 1 and 4-hours after injection. GBL, quinpirole, and sulpiride, were also
administered via IP injections and sacrificed 1-hour after injection.

2.3

Sacrificing Schedule and Brain Harvesting
In each experiment all animals were sacrificed using CO2 asphyxiation. Animals

were sacrificed on time intervals of 5-minutes to ensure a fixed incubation time for each
individual treatment. Each mouse was decapitated according to IACUC procedure and
the brain was removed from the skull. A coronal cut was made approximately 1mm
caudal to bregma, which separated the brain into two distinct regions (midbrain and
forebrain) from which tissue punches could be obtained. Both sections were immediately
frozen on dry ice for future sectioning.
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Figure 2.1 The previous schematic shows the regions of the brain which were excised
for analysis. The two outside circles represent the substantia nigra pars
compacta and the middle circle represents the ventral tegmental area.

2.4

Tissue Collection
Midbrain and forebrain sections were bound on a custom made cold aluminum

tissue slicer using Tissue-Tek O.C.T. compound, from which 300 μm sections were taken
(Fig 2.2). Bilateral punches were taken from the substantia nigra pars compacta and
ventral tegmental area, which were placed immediately in lysis buffer for future
extraction of RNA (Figure 2.1). Bilateral punches were also taken from the striatum and
nucleus accumbens to measure neurochemical changes using Waters HPLC detection.
Right striatum and nucleus accumbens punches were used to measure biopterin levels and
left striatum and nucleus accumbens punches were used to analyze catecholamine levels.
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Figure 2.2 Aluminum Tissue Slicer

2.5

RNA Extraction
To isolate RNA from the 1-hour samples an Absolutely RNA Microprep Kit

obtained from Stratagene was used in accordance to the directions indicated in the
instruction manual. An AllPrep RNA/Protein kit purchased from Qiagen was used to
extract RNA and protein from 4-hour haloperidol treated samples. RNA extracted in
both procedures was used in subsequent reactions to detect gene expression levels of the
Nur receptor genes.

2.6

Reverse Transcription and Quantitative PCR
Isolated RNA was used to make cDNA using an Omniscript RT Kit obtained from

Qiagen on the 1-hour haloperidol, 4-hour haloperidol, and GBl, quinpirole, and sulpiride
treatment groups. To obtain cDNA for quantitative reactions with the 1-hour dopamine
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agonist and antagonist treatment group, random nanomers obtained from Gene link were
used in replace of oligo dT’s in the Qiagen Omniscript RT Kit. This was done to increase
the amount of cDNA obtained in the reaction due to suspected sample quality concern.
cDNA was made by reverse transcribing our isolated RNA by the materials provided
within the Omniscript RT kit provided by Qiagen. Real time quantitative PCR was used
in order to measure and analyze gene expression levels of Nurr1, Nur77, and Nor1 in the
substantia nigra pars compacta and ventral tegmental area among different treatment
groups. -actin was also measured, which served as an internal control being that it is a
standard housekeeping gene. Lux primers obtained from Invitrogen were designed to
provide high specificity and sensitivity to our specific genes of interest (Table 2.2).
Systemic 1 hour haloperidol and dopamine agonist and antagonist injections were
analyzed using the iCycler iQ real-time PCR detection system from BioRad. The
expression levels of each gene were examined based on standard curves obtained from
fluorescently amplified PCR products of each gene of interest and normalized to -actin.
To determine the expression of the Nur77 receptor subfamily in the 4 hour haloperidol
treatment and Nurr1 +/+ or +/- mice the Strategene Mx3005p QPCR machine was used.
Platinum qPCR Supermix-UDG obtained from Invitrogen was used in both quantitative
experiments in amounts of 10.8μl per reaction.

2.7

HPLC Electrochemical Detection
Tetrahydrabiopterin, dopamine, HVA, and DOPAC levels were detected using the

Waters 2465 Electrochemical Detector system, in which absolute amounts of
catecholamines were determined based on the response to known standards. Detection of
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these neurochemical levels required to mobile phases: ROMP (pH 3.65), which consisted
of Sodium Phosphate Monobasic (Sigma), Sodium Octyl Sulfate (Sigma), EDTA,
disodium (Sigma), Methanol (Fisher), H20 (Millipore), Tryethylamine (Fluka) and
Biopterin (pH 5.22), which consisted of Sodium Acetate (Sigma), Citric Acid (Sigma),
EDTA (Sigma), 1,4 Dithioerythritol (Fluka), and Diethylenetriamine-pentaacetic acid
(Fluka). To detect tetrahydrobiopterin levels a biopterin standard was used in
conjunction with the biopterin mobile phase and to detect catecholamine levels Mix 9
(Dopamine, Serotonin, DOPAC, HVA, DOPA, MHPG, Norepenephrine, DHBA, 3MT,
5HIAA) obtained from Sigma was used in conjunction with ROMP. Brains were frozen
and mounted on a custom tissue slicer (Figure 2.2) which allowed sections to be cut
approximately 300μm thick. Tissue punches were then taken from the nucleus
accumbens and striatum and prepared for catecholamine and tetrahydrabiopterin analysis.
All data were analyzed and processed using Waters HPLC Empower software. One
tissue punch was suspended in 0.1 M perchloric acid, homogenized, centrifuged twice to
clear the supernatant and injected into a high pressure liquid chromatography (HPLC)
system consisting of a Waters 2695 Separation module, a Supleco LC-18-DB column
with the Waters 2465 electrochemical detector (ECD). The ECD was set at 20nA and an
Ec=+0.67V using a mobile phase of 100mM phosphate, 17.5% methanol, 25 mM EDTA,
1mM octyl sodium sulfate at pH 3.65. These conditions provided good separation and
detection of dopamine and its metabolites DOPAC and HVA. The other tissue punch
was used to measure BH4. The tissue was suspended in biopterin moile phase (50 mM
sodium acetate, 5mM citric acid, 5μM EDTA, 1mg/ml DTE and 1mg/ml DTPA at a pH
of 5.22), homogenized, and cleared by centrifugation. The supernatant was injected into
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the biopterin mobile phase. The quantity of each comp[ound was determined based on
the response of a known amount of standards. A Bradford assay was performed to
measure total protein for each tissue punch, which was used to normalize measurements
across samples. The Bradford reagent protein assay was performed on pellets formed on
the bottom of the microcentrifuge tubes from which the supernatant that was extracted for
HPLC analysis. To perform this reaction pellets were solubilized with 100μl of 0.5 M
NaOH by incubating at 37oC for 1hr. ddH2O was then added to the samples (200ul to
NuAcc samples and 100ul to Striatal samles) according to determined dilution capability
of each sample and incubated for an additional thirty minutes. The samples were loaded
into a 96-well plate and assayed using the ThermoMax microplate reader with Softmax
pro software. Bovine Serum Albumin was used as our standard.

2.8

Chemicals and Reagents

Haloperidol, -butyrolactone (GBl), quinpirole, and sulpiride were all obtained
from Sigma with 99% purity. 0.1M Acetic acid was used to dissolve haloperidol into
solution, which was then further diluted with saline to reach a final concentration
0.1mg/k.
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Table 2.2 D-Lux Select Primers (Invitrogen)
Nurr1

ATTGCTGCCCTGGCTATGGT_FL, GACCATGTGACTTTCAATAATAATGGG_RU

Nur77
Nor-1
-actin
VMAT2
TH
D2R
DDC
DAT

Invitrogen Designed Primers
Invitrogen Designed Primers
Invitrogen designed Primers
caccagAGACAGCTCCTTTCCTGGtG-forward ,GGATGGCTGGAGCACAAAGAG-reverse
gacattgCCCAGAGATGCAAGTCCAATGtC_FL, TGTTGGCTGACCGCACATTT_RU
catccaAGTGAACAGGCGGAGAATGGAtG_FL, AGGATGTGGCGATGATCCAG_RU
caccttCCAGTAGGGCCACCAAGGtG_FL, GGGAGGAGTGATCCAGGGAAGT_RU
cacataCCCCTGCTTCCTCCTGTATGtG_FL, AGGATGTGGCGATGATCCAG_RU
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CHAPTER III
RESULTS

Our first goal of interest was to successfully antagonize the D2 receptor to induce
the upregulation of the Nur receptor subfamily (Nurr1, Nor1, and Nur77) within the
substantia nigra pars compacta and ventral tegmental area and measure their expression
levels after a 1 hour incubation period. As described in the introduction Nurr1, Nor1, and
Nur77 are all inducible transcription factors, which are thought to play a major role in
dopaminergic neuron production and activity. To achieve this goal we used haloperidol
to antagonize the D2 receptor and induce the expression of the three members of the
nuclear receptor subfamily. As stated earlier haloperidol is a strong D2 receptor
antagonist, which will bind to both the presynaptic and postsynaptic receptors located on
dopaminergic neurons in the midbrain as well as within the dopaminoceptive areas such
as the striatum and nucleus accumbens. To conduct this experiment, 16 mice were
injected intraperitoneal with a 1mg/kg dose of a haloperidol acetic acid solution or a
saline solution. After a 1 hour incubation period each mice was mice was sacrificed and
brains were removed and immediately frozen on dry ice. To determine the relative
expression of each transcription factor quantitative real time PCR was used and all of our
data was normalized to -Actin, which served as our internal control.
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3.1

Nur77 Receptor Subfamily Expression levels and Neurochemical Changes at
1-Hour
The expression levels of Nur77 and Nor1 were shown to be significantly

increased in the substantia nigra pars compacta and ventral tegmental area in haloperidol
treated animals versus vehicle treated animals after 1h, which is consistent with the
results found by Maheux et. Al (Figures 3.1 & 3.2). However, there were no significant
changes found among Nurr1 in either the substantia nigra pars compacta nor the ventral
tegmental area, which was contradictory to previous research. Nur77 and Nor1 increased
expression levels also corresponded to neurochemical and metabolic changes within the
dopaminoceptive regions such as the striatum and nucleus accumbens. Tissue level
dopamine was found to be lower in haloperidol treated mice as compared to vehicle
treated mice in the nucleus accumbens and striatum, which corresponded with increased
release of dopamine resulting in an increase in metabolism as shown by an increase in
HVA and DOPAC due to the antagonistic effects induced by haloperidol on the D2
receptor (Figures 3.3 & 3.5). DOPAC levels were shown to be significantly increased in
the striatum after haloperidol treatment (Figure 3.3) and was not shown to be significant
in the nucleus accumbens (Figure 3.5). HVA levels were shown to be significantly
increased after haloperidol treatment groups in both the nucleus accumbens and striatum
(Figures 3.3 & 3.5). Dopamine turnover was found to be significantly higher in
haloperidol treated mice in both the striatum and nucleus accumbens suggesting that there
was an increase in the amount of dopamine being produced and released (Figures 3.4 &
3.6). Tetrahydrabiopterin levels were shown to be significantly higher for haloperidol
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treated mice in the nucleus accumbens while, there was no significant difference found in
the striatum among treatment groups (Figure 3.7).
haloperidol treated mice in the nucleus accumbens while, there was no significant
difference found in the striatum among treatment groups.

Figure 3.1 Nor1, Nur77, and Nurr1 gene expression levels in the substantia nigra pars
compacta after 1h injection with 1mg/kg haloperidol. This figure shows the
significant upregulation of Nor1 and Nur77 in the substantia nigra pars
compacta after induction with haloperidol compared to vehicle treated
animals. Nurr1 gene expression levels in the substantia nigra pars compacta
were shown to exhibit a non-significant trend for the upregulation of Nurr1 in
the substantia nigra pars compacta after haloperidol compared to vehicle
treated animals. All gene expression level data was normalized to -actin a
standard housekeeping gene. (*) Indicates significant differences from the
vehicle treated (p<0.05).
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Figure 3.2 Nor1, Nur77, and Nurr1 gene expression levels in the ventral tegmental area
1h after injection with 1mg/hg haloperidol. This figure shows the significant
upregulation of Nor1 and Nur77 in the ventral tegmental area after induction
with haloperidol compared to vehicle treated animals. Nurr1 gene expression
levels in the ventral tegmental area were shown to exhibit a non-significant
trend for the upregulation of Nurr1 in the ventral tegmental area after
induction with haloperidol compared to vehicle treated animals. All gene
expression level data was normalized to -Actin a standard housekeeping
gene. (*) Indicates significant differences from the vehicle treated (p<0.05).
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Figure 3.3 Dopamine (A), DOPAC (B), and HVA (C) levels are shown in the striatum
after 1h injection with 1mg/kg of haloperidol. A significant decrease in
dopamine levels were found in the striatum due to the increased release of
dopamine. Also haloperidol produced a significant increase levels of DOPAC
and HVA due to the increased release of dopamine. (*) Indicates significant
differences from the vehicle groups (p<0.05).

23

Figure 3.4 Dopamine turnover in the striatum as it relates to the metabolite DOPAC and
HVA. There was significantly greater dopamine turnover in the striatum
based on ratios of DOPAC/Dopamine, HVA/Dopamine, and
DOPAC+HVA/Dopamine. Combined dopamine turnover confirms that there
is a greater release and metabolism of dopamine in the striatum, therefore
producing an increase in the amount of DOPAC and HVA produced. (*)
Indicates significant differences from the vehicle groups (p<0.05).
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Figure 3.5 Dopamine (A), DOPAC (B), and HVA (C) levels are shown in the nucleus
accumbens 1h after injection of 1mg/kg haloperidol. A significant decrease
of dopamine levels were found in the nucleus accumbens to the increased
release of dopamine. Also haloperidol produced a significant increase of
HVA levels in the nucleus accumbens due to the increased release of
dopamine. DOPAC expression in the nucleus accumbens after did not show
any significant difference between treatment and non-treatment groups. (*)
Indicates significant differences from the vehicle treated (p<0.05).
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Figure 3.6 Dopamine turnover in the nucleus accumbens as it relates to the metabolite
DOPAC and HVA. . There was significantly greater dopamine turnover in
the nucleus accumbens based on ratios of DOPAC/Dopamine,
HVA/Dopamine, and DOPAC+HVA/Dopamine. Combined dopamine
turnover confirms that there is a greater release and metabolism of dopamine
in the nucleus accumbens, therefore producing an increase in the amount of
DOPAC and HVA produced. (*) Indicates significant differences from the
vehicle treated (p<0.05).
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Figure 3.7 Tetrahydrobiopterin levels in the striatum and nucleus accumbens 1h after
systemic injection of haloperidol. Tetrahydrobiopterin levels not significantly
higher in different treated mice in the striatum compared to haloperidol
treated mice indicating that dopamine production is not affected by
haloperidol in the nigrostriatal pathway. Although in the nucleus accumbens
tetrahydrobiopterin levels were found to be significantly higher in mice that
were given 1mg/kg injections of haloperidol indicating that dopamine
production may be upregulated in the mesolimbic pathway by increasing
tetrahydrobiopterin levels. (*) Indicates significant differences from the
vehicle treated (p<0.05).

3.2

Regulatory Gene Expression levels and Neurochemical Changes at 4-Hours
Gene expression levels of TH, DAT, DDC, VMAT, GTPCH and D2R were

measured 4hrs after haloperidol challenge. The time point of 4h was chosen to provide
sufficient time for the transcription factor RNA to be translated into protein and alter
expression of target gene RNA. This will give us insight into the regulatory control that
these genes could have on dopamine production. Dopamine and dopamine metabolite
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levels were also measured to assess the neurochemical changes that correspond to the
upregulation of regulatory gene control. Dopamine levels were found to be lower in
haloperidol treated groups in the striatum (Figure 3.8). In the nucleus accumbens the
levels of dopamine were higher in haloperidol treated mice (Figure 3.10). Dopamine
metabolite levels were shown to be significantly increased in both the striatum and
nucleus accumbens in mice who received the haloperidol treatment, which corresponded
to increased dopamine turnover levels in both regions for haloperidol treated animals
(Figures 3.9 &3.11). There were no significant changes in BH4 levels in the striatum or
nucleus accumbens although, biopterin levels did seem to be higher in the striatum in
mice treated with haloperidol (Figure 3.12).
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Figure 3.8 Dopamine (A), DOPAC (B), and HVA (C) levels in the striatum are shown
4h after injection with 1mg/kg of haloperidol. A significant decrease in
dopamine levels were found in the striatum due to the increased release of
dopamine. Also haloperidol produced a significant increase in DOPAC and
HVA levels due to the increased release of dopamine. (*) Indicates
significant differences from the vehicle treated (p<0.05).
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Figure 3.9 Dopamine turnover in the striatum as it relates to the metabolite DOPAC and
HVA 4h after a 1mg/kg systemic injection of haloperidol. There was
significantly greater dopamine turnover in the striatum based on ratios of
DOPAC/Dopamine, HVA/Dopamine, and DOPAC+HVA/Dopamine.
Combined dopamine turnover confirms that there is a greater release and
metabolism of dopamine in the striatum, therefore producing an increase in
the amount of DOPAC and HVA produced. (*) Indicates significant
differences from the vehicle treated (p<0.05).
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Figure 3.10 Dopamine (A), DOPAC (B), and HVA (C) levels in the nucleus accumbens
are shown 4h after a 1mg/kg systemic injection of haloperidol . A
significant increase in dopamine levels were found in the nucleus
accumbens indicating that increased release of dopamine from haloperidol
induction has ceased after a 4hr incubation period. Also haloperidol
produced a significant increase in DOPAC and HVA levels due to the initial
increased release of dopamine. (*) Indicates significant differences from the
vehicle treated (p<0.05).
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Figure 3.11 Dopamine turnover in the nucleus accumbens as it relates to the metabolite
DOPAC and HVA 4h after a 1mg/kg systemic injection of haloperidol.
There was significantly greater dopamine turnover in the nucleus accumbens
based on ratios of DOPAC/Dopamine, HVA/Dopamine, and
DOPAC+HVA/Dopamine indicating that dopamine turnover is still
upregulated 4h after treatment. Combined dopamine turnover confirms that
there is a greater release and metabolism of dopamine in the nucleus
accumbens, therefore producing an increase in the amount of DOPAC and
HVA produced. (*) Indicates significant differences from the vehicle
treated (p<0.05).
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Figure 3.12 Tetrahydrabiopterin levels in the striatum and nucleus accumbens 4h after a
1mg/kg systemic injection of haloperidol. Tetrahydrobiopterinm levels
were not significantly different in vehicle tereated mice in the striatum or
nucleus accumbens indicating that the need for increased dopamine
production has ceased in both the nigrostriatal and mesolimbic pathway. (*)
Indicates significant differences from the vehicle treated (p<0.05).
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Figure 3.13 Dopamine neuron gene expression in the substantia nigra pars compacta
after 4h after a 1mg/kg systemic injection of haloperidol. Significantly
reduced expression of dopamine transporter (DAT) was found to be present
after haloperidol treatment. Dopamine decarboxylase (DDC), and dopamine
D2 receptor were not shown to be significantly altered. Also tyrosine
hydroxylase and VMAT levels were found to be unmeasuarable, which is
not reflected in the graph shown. (*) Indicates significant differences from
the vehicle treated (p<0.05).
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Figure 3.14 Dopamine neuron gene expression in the ventral tegmental area 4h after a
1mg/kg systemic injection of haloperidol. Tyrosine hydroxylase (TH) and
dopamine transporter (DAT) shown to be significantly elevated after
haloperidol treatment. Dopamine decarboxylase (DDC) and dopamine D2
receptor were not shown to be significantly altered. (*) Indicates significant
differences from the vehicle treated (p<0.05).
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Figure 3.15 Dopamine neuron gene expression in the ventral tegmental area after a 1
mg/kg systemic injection is allowed incubate for 4hrs This graph shows the
nonsignificant increase of VMAT in the ventral tegmental area. (*)
Indicates significant differences from the vehicle treated (p<0.05).

3.3

Nur77 Receptor Subfamily Expression levels after D2R Agonist/Antagonist
Challenge

Nur77 receptor subfamily levels were measured after challenge with quinpirole, sulpiride,

or -butyrolacotne in order to try and elucidate the mechanisms of gene expression of the Nur
receptor subfamily. Due to tainted RNA quality exact measurements of gene expression levels
were compromised. Also, there were limited amounts of control samples available for
significance comparisons among treatment groups. In order to overcome these issues samples
were analyzed across plates and normalized to each other. After analysis we found that
quinpirole caused a significant reduction of Nurr1 compared to control samples. Sulpiride and butyrolactone did not cause any significant increases or decreases in expression of any one of the
three Nur receptor subfamily genes.
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Figure 3.16 The effects of quinpirole, -butyrolactone, and sulpiride on Nur receptor
subfamily expression. Quinpirole and -butyrolactone both show a trend to
cause a relative decreased level of expression of Nur77 and Nor-1 when
compared to control samples. Only quinpirole was found to produce a
significant change in Nur receptor expression levels. It was shown that
Nurr1 expression is significantly decreased in mice that received quinpirole
treatment versus those that received vehicle treatments. This decrease in
Nurr1 expression level could be due to stimulation of the D2 receptor by
quinpirole, which acts as an agonist. (*) Indicates significant differences
from the vehicle treated (p<0.05).

3.4

Neurochemical Effects of Dopamine Agonist and Antagonist Treatment in
the Striatum and Nucleus Accumbens
To access the neurochemical changes caused by dopamine altering activation of

the D2 autoreceptor, -butyrolactone (GBL), sulpiride, quinpirole, and saline was used to
challenge 32 mice. In the striatum it was found that dopamine was significantly
increased in mice treated with GBL and quinpirole compared to mice administered the
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vehicle treatment (Figure 3.17A). Sulpiride treated mice were shown to have the same
levels of dopamine in the striatum as mice treated with the vehicle (Figure 3.17A).
Dopac levels were significantly higher in the striatum after GBL and quinpirole treated
samples compared to vehicle treatments. Sulpiride did not alter DOPAC or HVA levels
in the striatum. Interestingly, HVA levels were significantly lower in the striatum of
quinpirole treated mice compared to vehicle treated animals (Figure 3.18). GBL,
however had no effect on HVA levels. Dopamine turnover was significantly decreased
by both GBL and quinpirole. Sulpiride had no significant effect on dopamine turnover.
In the nucleus accumbens, tissue dopamine levels of DOPAC were significantly higher in
GBL treated animals compared to vehicle treatments (Figure 3.19). GBL had no effect
on HVA levels in the nucleus accumbens. Dopamine and DOPAC levels were also
significantly elevated in the nucleus accumbens in quinpirole treated mice compared to
vehicle treated mice (Figure 3.19). Sulpiride had no effect on dopamine and HVA levels
but did elevate DOPAC levels when compared to vehicle treatements. Dopamine
turnover analysis showed indicated that GBL and quipirole significantly reduced
dopamine turnover while sulpiride sulpiride increased dopamine turnover in the nucleus
accumbens (Figure 3.20).
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Figure 3.17 Dopamine (A), DOPAC (B), and HVA (C) levels in the striatum 2h after butyrolactone (GBL), quinpirole, or sulpiride treatments. GBL and
quinpirole treated groups have a significantly higher amount of tissue
dopamine compared to control groups due to the reduced release of
dopamine. Sulpiride administered mice did not show any significant
changes related to dopamine when compared to mice that administered the
control treatment. Interestingly, GBL and quinpirole treated mice produced
significant increases in the amount of DOPAC produced from metabolized
dopamine when compared to control groups. Sulpiride administered mice
did not show any significant changes in DOPAC when compared to mice
administered the control treatment. Mice treated with quinpirole have
significant decreases in the amount of HVA when compared to control
groups. GBL and Sulpiride administered mice did not show any significant
changes of HVA levels when compared to mice administered the control
treatment. (*) Indicates significant differences from the vehicle treated
(p<0.05).
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Figure 3.18 Combined dopamine turnover (A), DOPAC/Dopamine (B), and
HVA/Dopamine (C) in the striatum 2h after -butyrolactone (GBL),
quinpirole, or sulpiride treatment. GBL and quinpirole treated groups
showed a significant decrease in the amount of dopamine turnover as it
relates to combined (HVA +DOPAC) metabolite production and individual
production of DOPAC and HVA when compared to vehicle treated groups.
Sulpiride administered mice showed a significant increase in the amount of
combined dopamine turnover and individual dopamine turnover as it relates
to DOPAC when compared to mice administered the control treatment
indicating that there is a increased amount of dopamine release and
transmission in the nigrostriatal pathway resulting in increased metabolism.
(*) Indicates significant differences from the vehicle treated (p<0.05).
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Figure 3.19 Dopamine (A), DOPAC (B), and HVA (C) levels in the nucleus accumbens
2h after -butyrolactone (GBL), quinpirole, or sulpiride treatments. GBL
and quinpirole treated groups have a significantly higher amount of tissue
dopamine compared to vehicle treated groups due to the blocked and
reduced release of dopamine. Sulpiride administered mice did not show any
significant changes related to dopamine when compared to mice that
administered the control treatment only a trend to have less measurable
tissue levels of dopamine. Interestingly, GBL, quinpirole, and sulpiride
treated groups showed significant increases in the amount of DOPAC
produced from metabolized dopamine when compared to vehicle treatments,
indicating that dopamine levels have risen due to some stimulus. Treated
mice showed no significant increases or decreases in the amount of HVA
produced from metabolized dopamine when compared to vehicle treatments.
(*) Indicates significant differences from the vehicle treated (p<0.05).
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Figure 3.20 Combined dopamine turnover (A), DOPAC/Dopamine (B), and
HVA/Dopamine (C) in the nucleus accumbens 2h after -butyrolactone
(GBL), quinpirole, or sulpiride treatment. GBL and quinpirole treated
groups have a significant decrease in the amount of dopamine turnover as it
relates to combined (HVA +DOPAC) metabolite production and individual
production of DOPAC and HVA when compared to vehicle treatments.
Sulpiride administered mice show a significant increase in the amount of
combined dopamine turnover and individual dopamine turnover as it relates
to DOPAC and HVA when compared to mice administered the vehicle
treatment indicating that there is a greater release of dopamine in the
mesolimbic pathway resulting in increased metabolism. (*) Indicates
significant differences from the vehicle treated (p<0.05).
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Figure 3.21 Tetrahydrabiopterin levels in the nucleus accumbens and striatum. Tissue
punches from the both regions were prepared for HPLC analysis then
quantified using waters 2465 electrochemical detector. Significant lower
levels of biopterin were shown to be present in striatal punches of GBL
samples, indicating that the blocked release of dopamine has not produced
an extra need for the cofactor. Quinpirole and sulpiride samples did not
show any significant effects when compared to control group animals.
However in the nucleus accumbens significant lower levels of biopterin
were shown to be present in nucleus accumbens punches of quinpirole
samples, indicating that the reduced release of dopamine has not produced
an extra need for the cofactor. Sulpiride and GBL samples did not show any
significant effects when compared to control group animals. (*) Indicates
significant differences from the vehicle treated (p<0.05).

3.5

Effects of altered Nurr1 expression on Nur77 and Nor-1 receptor expression
levels
It is known that Nurr1 plays a major role in regulation of dopamine neuron

production and survival. Whether or not Nur77 and Nor-1 can compensate for Nurr1
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malfunction remains an unanswered question. Since Nur77 and Nor1 possess some of
the same similar DNA binding domains and transactivation properties it is thought that
they may be able to elevate their expression levels in times when Nurr1 levels drop. To
investigate this theory we performed experiments using Nurr1 +/+ and +/- mice in order
to determine if there were any significant change of expression levels in Nur77 and Nor1.
We found that there was no change in the expression levels of Nur77 and Nor1 in either
the substantia nigra in Nurr1 +/+ and +/- mice (Figure 3.22). This indicates that even
though Nurr1 +/- mice have an incomplete copy of the Nurr1 gene, Nur77 and Nor1
expression levels remain at basal conditions.
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Figure 3.22 Expression levels of Nur77 and Nor1 from the substantia nigra Nurr1 +/+
and +/- mice. Quantitative real time PCR was used in order to quantify
expression levels of each gene, which were normalized to internal standard
control -actin. There were no significant differences found in expression
of either due to the Nurr1 genotype. (*) Indicates significant differences
from the vehicle treated (p<0.05).
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CHAPTER IV
DISCUSSION AND CONCLUSIONS

4.1

Discussion
Nurr1 is fundamental to the proper development and sustainability of dopamine

neurons in the midbrain regions of the substantia nigra and the ventral tegmental area.
Therefore, its function and regulation could be important in the pathology of certain
neurological disorders such as Parkinson’s, schizophrenia, attention deficit disorder, and
other diseases which are related to dopamine neuron function and transmission. Nor-1
and Nur77 are both nuclear transcription factors related to Nurr1 but are concentrated
within the dopaminoceptive regions (striatum and nucleus accumbens). As all three share
structural and functional domains and DNA binding properties (Zetterstrom et al. 1996b;
Beaudry et al. 2000; Milbrandt et al. 1988; Law et al. 1992; Ohkura et al. 1994, Wilson et
al. 1991; Paulsen et al. 1995; Zetterstrom et al. 1996a) changes in the expression of these
genes in dopamine neurons must be considered as regulating similar target genes.
Although the role of these proteins is as transcription factors, little is known about
the target genes they regulate. Because Nurr1 is essential for proper differentiation and
function of dopamine neurons, it is important to understand the genes and dopamine
neuron functions regulated by the Nur-receptors. Nurr1 has been directly related to TH,
DAT, VMAT, GTPCH, and DDC which are all specific markers necessary for dopamine
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synthesis and regulation (Zetterstrom et al. 1996a, Saucedo-Cardenas et al. 1998, Castillo
et al. 1998, Eells et al, 2006, Gil et al., 2007). Many of these relationships, however, are
either indirect, based on in vitro transfection assays or cell-lines in culture.
In addition to being transcription factors, the Nur-receptors are also considered
immediate early genes, meaning that there promoter regions have response elements
through which expression can be increased without the need for protein synthesis (Eells
et al. 2000). The most notable immediate early gene is c-fos whose activation is
dependent on early response element CArG (Rivera et al. 1990). c-Fos has been shown
to be directly related to neuronal firing of action potentials. Previous research has shown
that Nur77, Nor-1, and c-Fos mRNA is increased in the nucleus accumbens and caudate
putamen after acute haloperidol administration (Werme et al. 2000). Also, Maheux et al.
(2004) reports that acute administration of antipsychotic drugs, at doses likely to produce
extrapyramidal symptoms drastically increases c-Fos mRNA levels in the striatum.
Another member of the Fos family, Fos-B, has been shown to have possible regulatory
control of TH expression in olfactory dopaminergic neurons via AP-1 and CRE motifs,
both of which has been shown to be present in the promoter regions of each member of
the Nur receptor subfamily (Liu et al. 1998 and Eells et al. 2000). Currently, there is
limited data on the parameters that regulate the expression of the Nur-receptors in
dopamine neurons in vivo.

4.1.1

Gene expression after Haloperidol
The current studies examined the expression of the Nur-receptors one hour and 4

hours after haloperidol treatment. Additionally, the expression of potential target genes
was also examined. Our findings indicated that there was an elevated expression of
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Nur77 and Nor1 in the substantia nigra pars compacta and ventral tegmental area 1h after
a systemic injection of haloperidol was allowed to incubate for 1 hour. No significant
difference in Nurr1 expression in either the substantia nigra pars compacta of the ventral
tegmental area was found in the current study. Previous research has indicated similar
findings (increases in Nur77 and Nor1) along with increases in Nurr1 in both regions of
the midbrain (Maheux et al. 2004). One possible explanation for differences found
among nurr1 expression could be the method used. In the current study, real time PCR
was used to detect changes among gene expression in the midbrain which provided us
with a measurement of expression from RNA isolated from the dissection of either the
substantia nigra or ventral tegmental area. Maheux et al. used in situ hybridization which
has better anatomical resolution and gives expression levels for individual neurons. In
situ hybridization, however, samples are not normalized to a housekeeping gene the way
quantitative PCR is. Additionally, at basal levels, Nur77 and Nor-1 expression is barely
detectable; therefore the percent increase will be greater than that of Nurr1, which may
help explain why there was no significant increase found for Nurr1 in our analysis.
Additionally, Maheux et al., used rats and the current study used mice so that there could
be subtle species differences.
Since Nur77 and Nor-1 possess the ability to bind to the same promoter regions as
Nurr1, any increases in the receptor molecules should affect the regulation of many of the
same genes that are controlled by Nurr1. To test this hypothesis, samples from the 4 hour
haloperidol experiment were analyzed to provide data that would show how much if any
up-regulation of dopamine neuron genes was occurring. Previous research has
demonstrated that TH gene expression can be directly regulated by Nurr1 ( Sakudurada et
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al. 1999; Cazorla et al. 2000). Nurr1 has been shown to transactivate the promoter
activity of the TH gene in different cell line indicating that the TH promoter region
contains known sequences of NBRE, which is the DNA binding domain of Nurr1 (Kim et
al. 2003). Additional research has indicated that TH and Nurr1 mRNA is elevated in the
substantia nigra pars compacta along with Nurr1 mRNA levels being elevated in the
ventral tegmental area also after systemic haloperidol treatment in Nur77 -/- mice
(Gilbert et al. 2006). This previous research suggests that with a lack of Nur77, Nurr1
expression is upregulated in order to compensate for the loss of Nur77. It also shows
that haloperidol is able to induce a need for higher amounts of dopamine during periods
of Nur77 dysfunction. However, other research reports no change in TH mRNA after
chronic administration of haloperidol, which was probably due to tolerance formed by
dopamine D2 receptors from constant stimulation by haloperidol (Cho et al. 1999). Also
TH mRNA expression is significantly reduced in vivo in Nurr1 +/- mice with a
corresponding decrease in TH activity in the striatum (Eells et al. 2006). Based on the
current data, Nur77 and Nor1 could be factors that regulate TH expression. TH
expression however, may be regulated differently by the Nur-receptors between
nigrostriatal dopamine neurons and mesolimbic dopamine neurons.
The role for the Nur- receptors in DAT regulation is not as straightforward. No
differences in DAT expression was found in either the substantia nigra pars compacta or
ventral tegmental area of the Nurr1 +/- mice. This, however, does not rule out the
possibility that transient induction of the Nur-receptors could induce DAT expression.
Bannon et al suggests a role for Nurr1 in DAT regulation of cocaine users who have
Nurr1 deficiency’s due to chronic use of the drug. Their research found that cocaine
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abusers who had deficiencies in Nurr1 also had reduced DAT expression (Bannon et al.
2001). The transcriptional activity of hDAT has been shown to be enhanced by Nurr1
(Sacchetti et al. 1999). Previous research also directly demonstrated that Nur77 and
Nurr1 increases expression of the hDAT gene in SN4741 dopamine cell lines although
Nurr1 effects are greater than that of Nur77 (Sacchetti et al. 2000). It remains to be
determined if Nor1 could share similar properties with Nurr1 involving the regulation of
DAT.
The previous research mentioned has shown that TH and DAT both could be
regulated by Nurr1 indicating that these genes possess NBRE response elements that can
be bound and activated by Nurr1 and quite possibly other members of the Nur receptor
subfamily. Interpretation of these results indicates that regulation of dopamine
neurotransmission can be inhibited and enhanced at various steps, starting at dopamine
neuron maturation, synthesis of dopamine, and finally transmission of the
neurotransmitter at its destination.
By comparing gene expression with neurochemical data, our findings indicate that
elevated Nur77 and Nor-1 expression corresponds to an increase in dopamine release,
turnover and, based on previous reports, dopamine synthesis. The neurochemical effects
from 1 hour of systemic haloperidol administration were decreased levels of dopamine in
both the striatum and nucleus accumbens. A 4 h systemic haloperidol administration
resulted in decreased dopamine levels in the striatum but an increase in dopamine levels
in the nucleus accumbens. Our findings suggest that the longer-term response to
haloperidol is different between the nigrostriatal and mesolimbic dopamine systems.
One possible explanation for this difference could be the function of the D2R
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autoreceptor in various dopamine neurons. Recently Lammel et al. (2008) found
differential expression and function of the D2R autoreceptor between mesolimbic/cortical
and nigrostriatal dopamine neurons. Although other differences have also been
described, this may explain differential effects of haloperidol between the nigrostriatal
and mesocortico limbic systems.
(BH4) was measured in both experiments of 1-hour and 4-hours after systemic
haloperidol administration. Our findings indicate that BH4 levels are significantly
elevated in the nucleus accumbens of haloperidol treated mice when compared to vehicle
treated mice 1h after injection. Haloperidol had no effect on BH4 in the striatum at 1 h or
the striatum or nucleus accumbens at 4 hours. This differential regional effect on BH4
levels after haloperidol may help explain the elevated dopamine levels in the nucleus
accumbens 4 h after haloperidol injection. BH4 is a necessary cofactor for TH for the
conversion of tyrosine to DOPA and is normally found at limiting concentrations such
that an increase or decrease in BH4 can either increase or decrease dopamine synthesis,
respectively. If the response of synapses in the nucleus accumbens is a rapid (1h) increase
in BH4 after haloperidol, this could cause a further increase in dopamine synthesis
resulting in greater dopamine levels 4 h later. In contrast, within the striatum, there was
no change in BH4 levels as a result of haloperidol treatment and a reduction in dopamine
levels 4 h after haloperidol. Fluctuations in BH4 levels in the mesoaccumbens pathway,
could, therefore represent an important mechanism to regulate dopamine synthesis in
response to acute antipsychotic treatments. This is the only data available, to our
knowledge, linking antipsychotics with alterations in BH4 levels.
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4.1.2

The effects of GBL, dopamine agonists and antagonists
Although antagonism of the D2 receptor can elevate expression of Nurr1, Nur77,

and Nor1 in dopamine neurons in vivo, it is still unclear the precise mechanism for this.
To investigate the activation properties of these genes we used a combination of D2
receptor agonist and antagonist treatments to determine the different effects each would
have on Nur-receptor expression in the dopaminergic system along with the
neurochemical effects. Quinpirole, a D2 receptor agonist, should stimulate presynaptic
autoreceptors therefore decreasing the rate of dopamine synthesis, release, and
subsequent dopamine turnover. Sulpiride a strong D2 receptor antagonist, should have
the same antagonistic effects as haloperidol. It was expected that due to blockage of
autoreceptor function, dopamine synthesis should be elevated along with increased
release followed by elevated dopamine turnover. GBL acts essentially as a dopamine
autoreceptor antagonist but does this by blocking dopamine release. Although both GBL
and sulpride inhibit the stimulation of the autorecpetor, they have opposite effects on
dopamine release.
Our findings indicate that there was a significant decrease in Nurr1 expression in
quinpirole treated mice when compared to vehicle treated mice. This decease could be
due to presynaptic D2 receptor stimulation which would inhibit any intracellular
signaling for increased dopamine synthesis, consequently down regulating genes
necessary for dopamine synthesis or could be the result of accumulation of dopamine or
alterations in electrical activity in dopamine neurons due to stimulating the D2 receptor.
No effect on Nurr77 or Nor1 was observed. As stated earlier, Nur77 and Nor1 expression
is already barely detectable in the midbrain at basal conditions. Treatment with
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quinpirole is expected to decrease any expression that is present, making it that more
difficult to detect expression signals by the methods that we have chosen. The effects of
quinpirole on dopamine neurochemistry included higher levels of dopamine in the
striatum and nucleus accumbens due to reduced release of dopamine from presynaptic
neurons, i.e. reduced dopamine turnover. This results in a significant increase of
intracellular dopamine similar to what was previously reported for the striatum and
nucleus accumbens of Nurr1 +/+ and +/- mice after quinpirole treatment (Eells et al.,
2006)
In this experiment, sulpiride failed to elevate expression of any of the Nurreceptor genes as haloperidol did in the previous experiment. The explanation may be
differences in receptor affinity and/or dose used. Since haloperidol has a higher affinity
for the D2 receptor, it may have a greater effect on Nur-receptor expression as well.
Based on neurochemical data, haloperidol had significant impact on dopamine
neurochemistry, increasing dopamine release as indicated by reduced tissue dopamine
and increased metabolites. Sulpiride, however, had no significant effect on dopamine
neurochemistry. It seems that sulpiride is not a strong enough antagonist of the D2
receptor or at a high enough dose to cause the excess stimulated release of dopamine as
haloperidol. These data suggest that a certain level of impact on D2 receptors and
subsequent dopamine neurochemistry is necessary to induce expression of the Nurreceptor genes.
As expected, GBL treatment significantly elevated DOPAC, as would be expected
as DOPAC is the primary intracellular metabolite of dopamine, and elevated dopamine
levels. Overall this significantly reduced dopamine turnover similarly in the striatum and
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nucleus accumbens. No Nur-receptor expression differences were found after GBL
treatment although these significant neurochemical changes were observed. Therefore, if
antagonism of the D2 receptor alone is the direct mechanism for induction of Nurreceptor genes, then GBL should have caused elevated Nur-receptor subfamily
expression similar to haloperidol. Because it did not suggests that other mechanisms such
as intracellular dopamine levels and/or electrical activity of dopamine neurons may also
contribute to regulation of Nur receptor gene expression.
In addition to determining levels of dopamine and metabolites, BH4 levels were
also measured after these treatments to give an indication of a key component of
dopamine synthesis. Our data show that in the striatum GBL treated mice contained
significantly decreased levels of BH4 compared to vehicle samples. However, in the
nucleus accumbens only quipirole treated mice were shown to have significantly lower
amounts of BH4, which is opposite of what we expected to happen since dopamine
synthesis should be decreased when a D2 receptor agonist is administered. However,
again there is significant activity present in the mesolimbic pathway as opposed to the
nigrostriatal pathway.

4.1.3

Relationship between Nurr1 expression and Nur77 and Nor1
Complete abolishment of Nurr1 (Nurr1-/-) inhibits terminal dopaminergic neuron

differentiation and results in the absence of midbrain dopamine (Eells 2003). Since
Nurr77 and NOR-1 share similar DNA binding domain regions as Nurr1, it is often
questioned whether Nurr77 and NOR-1 can compensate for an incomplete Nurr1 gene.
Experiments with Nurr1 +/+ and Nurr1 +/- mice were done in order to access whether or
not Nur77 and Nor-1 expression is altered due to a chronic reduction in Nurr1 caused by
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the Nurr1 +/- genotype. We found no significant differences in Nur77 and NOR-1
expression between Nurr1 +/- and Nurr1 +/+ mice in either the substantia nigra or the
ventral tegmental area. This indicates that Nur77 and NOR-1 expression remains
unchanged even after one copy of Nurr1 has been removed. Therefore, although the Nurreceptors have similar DNA binding properties and functions, there does not appear to be
regulation of Nurr1 at the promoter regions of Nur77 or Nor-1. Similarly, since the Nurr1
+/- genotype also alters a number of parameters of dopamine neuron function (Eells et al.,
2006 and Moore et al., 2008) these changes are also insufficient to affect Nur77, Nor-1 or
Nurr1 expression.

4.2

Conclusion
The Nur-receptors can be altered in dopamine neurons in vivo as the result of D2

receptor antagonism and stimulation. Whether this is directly related to actions at the
receptor or the neurochemical and/or electrophysiological consequences of modifying the
activity of the receptors remains to be determined. The current data suggests that the
neurochemical changes may be involved as GBL, which reduced dopamine release and
therefore autoreceptor activation, did not alter Nur receptor expression when direct
antagonism with of the D2R elevated Nur77 and Nor1 expression. The longer term
consequences of an increase in Nur receptor expression could include regulation of
dopamine neurotransmission genes as TH and DAT were elevated in a manner consistent
with previous elevation in Nur77 and Nor1. By studying Nur77 and Nor-1 expression in
Nurr1 +/- mice we found no evidence of cross regulation of Nurr1 effecting Nur77 and
Nor-1 expression. Further study on the direct mechanism responsible for inducing Nur-
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receptor expression and the consequences on gene expression and dopamine neuron
function continue.
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